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A B S T R A C T
Purpose: Electrographic seizures (ES) and electrographic status epilepticus (ESE) are common in
encephalopathic children in the pediatric intensive care unit (PICU) and associated with worse short-
term outcome. Survey data indicate most physicians treat ES and ESE with antiepileptic drugs (AEDs),
but few data are available regarding AED usage patterns. We aimed to describe AED usage for ES and ESE
in critically ill children.
Methods: We performed an observational study of patients who underwent continuous electroenceph-
alographic (cEEG) monitoring in the PICU of a single quaternary care children’s hospital. We collected
data regarding age, clinical diagnoses, ES and ESE occurrence, and AEDs utilized.
Results: 200 subjects underwent cEEG. ES occurred in 21% (41/200) and ESE occurred in 22% (43/200). Of
the 84 patients with ES or ESE, 80 received non-benzodiazepine AEDs including 48% (38 of 80) with ES
and 52% (42 of 80) with ESE. The most commonly administered ﬁrst AEDs were levetiracetam in 38% (30/
80), phenobarbital in 31% (25/80), phenytoin–fosphenytoin in 28% (22/80), and valproate in 4% (3/80).
Seizures terminated after administration of the ﬁrst AED in 74% (28/38) with ES and 22% (9/41) with ESE.
Conclusions: Levetiracetam, phenobarbital, and phenytoin–fosphenytoin are commonly used to manage
ES and ESE at our center. Over half of subjects received multiple AEDs.
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Continuous EEG monitoring (cEEG) is often utilized to identify
electrographic seizures (ES) and electrographic status epilepticus
(ESE) in children in the pediatric intensive care unit (PICU),1 and
recent survey data indicate cEEG use is increasing in North
America.2 ES and ESE occur in 7–47% of critically ill children who
undergo cEEG3–14 and several studies have reported an association
between ES and ESE and worse short-term outcome.13–16 When
surveyed, most physicians reported that they initiated antiepilep-
tic drugs (AEDs) in response to ES or ESE, but there was substantial
variability in the speciﬁc AEDs they reported administering.17
Further, survey responses may not reﬂect true practice. Data
regarding AED usage patterns will help guide clinical management
and develop feasible prospective AED effectiveness studies. We* Corresponding author at: Division of Neurology, The Children’s Hospital of
Philadelphia, 34th Street and Civic Center Blvd, Philadelphia, PA 19104, United
States. Tel.: +1 215 590 1719; fax: +1 215 590 1771.
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children in our PICU.
2. Patients and methods
Children treated in the PICU of a quaternary care referral
hospital who underwent clinically indicated cEEG between July
2008 and January 2011 were enrolled in a prospective observa-
tional study aimed at identifying ES-ESE risk factors18 and the
impact of ES-ESE on short-term outcome.15 Informed written
consent was obtained from the parents/guardians of patients for
inclusion in the database. Neonates (<1 month) were excluded.
This study was approved by the Children’s Hospital of Philadelphia
Institutional Review Board.
Our institution’s criteria for cEEG in the PICU were: (1) altered
mental status persisting for 1–2 h after a convulsion or convulsive
status epilepticus, (2) altered mental status without a preceding
convulsion in a patient with an acute neurologic disorder, or (3)
altered mental status and the presence of abnormal movements or
vital sign ﬂuctuations of unknown etiology. Per our clinical
pathway, patients underwent cEEG for at least 24 h when
screening for ES, unless they were undergoing therapeuticnder CC BY-NC-ND license.
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were monitored for 72 h. Patients with ES or ESE identiﬁed by cEEG
were monitored for approximately 24 h after their last seizure.
Continuous EEG monitoring was performed using a Grass-
Telefactor (Grass Technology, West Warwick, RI) video-EEG
system with 21 gold-over-silver scalp surface electrodes posi-
tioned according to the international 10–20 system and afﬁxed
with collodion adhesive. EEGs were interpreted by the Neuro-
physiology Service. Patients were managed by the Critical Care and
Neurology Consult services. There is no institutional pathway for
ES or ESE management so each physician made independent
management decisions. Prophylactic AEDs are not administered.
Clinical and EEG data were prospectively collected including
patient age, underlying acute neurologic disorder category, EEG
ﬁndings including ES or ESE occurrence, and AED usage. Patients
were assigned to one acute neurologic disorder category: (1)
history of epilepsy with altered mental status following a seizure
or status epilepticus, (2) hypoxic ischemic encephalopathy, (3)
encephalitis, (4) traumatic brain injury, (5) stroke, (6) sepsis, (7)
posterior reversible leukoencephalopathy syndrome, (8) neuro-
surgical procedure, (9) provoked seizures (such as febrile seizures),
or (10) systemic/metabolic disorders (such as electrolyte abnor-
malities or hepatic encephalopathy). EEG tracings were reviewed
by an investigator to provide standardized categorization of ES and
ESE. Seizures were classiﬁed as ES or ESE based on the seizure
burden at the administration time of the initial AED. ES was
deﬁned as an abnormal paroxysmal EEG event that was different
from the background lasting longer than 10 s with a temporal-
spatial evolution in morphology, frequency, and amplitude, and
with a plausible electrographic ﬁeld. ESE was deﬁned as either a
single 30-min ES or a series of recurrent independent ES totaling
more than 30 min in any 1-h period (50% seizure burden).
We performed an exploratory analysis of seizure termination
following administration of an initial AED. We described the use of
intravenous benzodiazepines and AEDs. Patients received benzo-
diazepines for both sedation and seizures, but delineation of
reason was not possible from the chart review. AED’s described
were levetiracetam, phenobarbital, phenytoin/fosphenytoin and
valproate. An AED was considered effective if within 30 min of AED
administration the patient became seizure free and had no seizure
recurrence for at least 12 h without administration of any new
AED. During the 12 h seizure-free period AED maintenance doses
and benzodiazepines could be administered.
Descriptive statistics are reported as median and interquartile
ranges (IQR) for non-parametric data. The Chi-squared or Fishers
Exact tests were used to determine the association between
categorical variables. The Wilcoxon rank-sum and Kruskal–Wallis
tests were used to test the association between continuous non-
parametric data.Table 1
Descriptive characteristics of subjects who received AEDs.
Variable All N = 80 
Age (years) median (IQR) 2.2 (0.6, 8.1) 
Male 46 (58%) 
AEDs prior to hospitalization 22 (28%) 
Acute neurologic disorder
Epilepsy 23 (29%) 
Hypoxic ischemic encephalopathy 15 (19%) 
Infection-autoimmune 10 (13%) 
Stroke 7 (9%) 
Traumatic brain injury 6 (8%) 
Metabolic–systemic 6 (8%) 
Neurosurgical procedure 5 (6%) 
Posterior reversible encephalopathy syndrome 3 (4%) 
Provoked seizures 3 (4%) 
Sepsis 2 (3%) 3. Results
During the study period 241 patients underwent cEEG. Forty-
one were not enrolled due to refusal (4), legal guardianship issues
(2), lack of study staff available for enrollment during their
hospitalization (17), or lack of parents available at bedside for in-
person consent (18). This led to 200 enrolled subjects. ES occurred
in 41 of 200 (21%) and ESE occurred in 43 of 200 (22%). AEDs were
administered during cEEG to 95% (80 of 84) of subjects with ES or
ESE including 48% (38 of 80) with ES and 52% (42 of 80) with ESE.
Four subjects with seizures (3 with ES and 1 with ESE) did not
receive AEDs: three had brief ES which resolved prior to treatment
including 1 with stroke, 2 with hypoxic ischemic encephalopathy,
and one with ESE hypoxic ischemic encephalopathy who had
withdrawal of technologic support prior to seizure treatment.
Descriptive characteristics regarding the 80 subjects who received
AEDs are provided in Table 1. Prior to ES or ESE onset,
benzodiazepines were being administered for sedation to 59%
(47 of 80) of subjects. Midazolam was the only benzodiazepine
administered as an infusion while boluses included diazepam,
lorazepam, and midazolam. Once ES or ESE were identiﬁed, most
patients continued to receive bolus doses of benzodiazepine but
the indication (seizure management versus sedation) could not be
determined from chart review so efﬁcacy analyses were not
performed. The most commonly administered ﬁrst AEDs were
levetiracetam in 38% (30 of 80) of subjects at a median dose of
23 mg/kg intravenously (IQR 20, 30), phenobarbital in 31% (25 of
80) of subjects at a median dose of 20 mg/kg intravenously (IQR 12,
23), phenytoin–fosphenytoin in 28% (22 of 80) of subjects at a
median dose of 20 mg/kg intravenously (IQR 14, 20), and valproate
in 4% (3 of 80) of subjects at a median dose of 22 mg/kg
intravenously (IQR 20, 30) (Fig. 1). Phenobarbital was the ﬁrst AED
given to younger children with a median age 0.25 years (IQR 0.17,
0.5), compared to phenytoin–fosphenytoin at 4.6 years (IQR 1.75,
10) and levetiracetam at 5.4 years (IQR 1, 10) (p < 0.001). There
was no difference in the frequency of AED administered based on
gender (p = 0.17) or seizure classiﬁcation as ES or ESE (p = 0.13).
Of the 80 subjects administered AEDs, 48% (38 of 80) received
one AED, 23% (18 of 80) received two AEDs, 8% (7 of 80) received
three AEDs, and 21% (17 of 80) received 4 AEDs (Fig. 2). Of the 38
subjects with ES, 76% (29 of 38) received one AED, 16% (6 of 38)
received two AEDs, 5% (2 of 38) received 3 AEDs, and 3% (1 of 38)
received 4 AEDs. Of the 42 subjects with ESE, 21% (9 of 42)
received one AED, 29% (12 of 42) received two AEDs, 12% (5 of 42)
received 3 AEDs, and 38% (16 of 42) received 4 AEDs. ESE
management required pentobarbital infusion, midazolam infusion,
or isoﬂurane in 26% (11 of 42) subjects. Seizures terminated after
administration of the ﬁrst AED in 46% (37 of 80) of subjects
including 74% (28 of 38) with ES and 21% (9 of 42) with ESE. OneES (38 of 80, 48%) ESE (42 of 80, 52%)
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Fig. 1. Initial antiepileptic drug administered.
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not administered additional AEDs, explaining the discrepancy
between 38 receiving one AED and only 37 having ES terminated
by the ﬁrst AED.
We performed exploratory analyses of seizure termination
following administration of various ﬁrst AEDs. In this single center
cohort, we failed to demonstrate a signiﬁcant difference in seizure
termination depending on the ﬁrst administered AED (phenobar-
bital 64% (16 of 25), levetiracetam 40% (12 of 30), phenytoin–
fosphenytoin 36% (8 of 22), and valproate 33% (1 of 3) (p = 0.19)).
Furthermore, we failed to demonstrate a signiﬁcant difference in
the efﬁcacy of any ﬁrst administered AED to terminate ES (p = 0.58)
or ESE (p = 0.47). For each of the ﬁrst administered AEDs, we failed
to demonstrate a signiﬁcant difference in the median dose
between those in whom seizures did and did not terminate:
phenobarbital (21 mg/kg vs. 20 mg/kg, p = 0.28), levetiracetam
(28 mg/kg vs. 20 mg/kg, p = 0.12), phenytoin–fosphenytoin
(20 mg/kg vs. 19 mg/kg, p = 0.19), and valproate (30 mg/kg vs.
21 mg/kg, p = 0.22).
4. Discussion
This single center observational study of children with acute
encephalopathy undergoing cEEG demonstrated levetiracetam,
phenobarbital and phenytoin–fosphenytoin are used with
similar frequencies, although phenobarbital is administered
more often to younger children. ES terminated after adminis-
tration of the ﬁrst AED in 74% of children while ESE terminated
after administration of the ﬁrst AED in only 21% of children.
Exploratory analysis in this small cohort failed to demonstrate a
signiﬁcant difference in seizure termination after administration
of any of the ﬁrst AEDs.48
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Fig. 2. Number of antiepileptic drugs (AED) administered.When surveyed, the majority of neurologists indicate that
they initiate an AED after a single ES is identiﬁed, and the
majority aim to terminate all ES, escalating to utilize multiple
AEDs and even pharmacologic coma induction for ES or ESE
refractory to two or three typical AEDs.17 Those survey data are
consistent with data from actual practice which indicated that
the most common change to clinical management as a result of
cEEG was AED adjustment.19 The current data demonstrate that
when ES or ESE were identiﬁed most patients at our center
received AEDs. These ﬁndings are in line with the recent
Neurocritical Care Society guidelines for the evaluation and
management of status epilepticus which describe that ‘‘treat-
ment of status epilepticus should occur. . . until electrographic
seizures are halted.’’20
Survey data indicate that lorazepam, phenytoin–fospheny-
toin, and levetiracetam are the most commonly utilized AED
when ES or ESE are identiﬁed.17 However, reported use in surveys
may not accurately reﬂect true clinical practice. Although many
subjects in our cohort were receiving benzodiazepines for
sedation prior to seizure identiﬁcation and continued to receive
benzodiazepines for sedation after seizure identiﬁcation, we
could not determine if benzodiazepine boluses were routinely
administered or if infusions were routinely escalated due to ES or
ESE. Instead, levetiracetam, phenobarbital, and phenytoin–
fosphenytoin were commonly administered when ES or ESE
were identiﬁed, partially establishing a state of clinical equipoise
needed for future clinical trials at our institution. Recent
guidelines regarding the management of convulsive and electro-
graphic status epilepticus suggest that benzodiazepines should
be given as emergent initial therapy and that most patients
should also receive ‘‘urgent control therapy’’ with fosphenytoin–
phenytoin, valproate sodium, or levetiracetam.20 Our cohort was
managed prior to publication of these guidelines and subjects
generally received ‘‘urgent control therapy.’’ The variability in the
AED chosen for ‘‘urgent control therapy’’ is consistent with
surveys21 and observational studies22 of status epilepticus
management. While few conclusions can be drawn regarding
effectiveness from these open-label observational data, there
is at least a suggestion that no AED had substantially better
efﬁcacy than the other AEDs. The variability in management
along with no clear signal regarding efﬁcacy help establish that
prospective rigorous comparative effectiveness investigations
are necessary.
These data demonstrate that only about half of patients with
ES and a quarter of patients with ESE had seizure termination
after a single AED, and polypharmacy is often required at our
center. Further, seizures terminated after administration of
each AED in only about 30–60% of patients. While this response
is disappointingly low, it is consistent with studies of AED
efﬁcacy in other populations. In a study of neonatal seizures,
N.S. Abend et al. / Seizure 22 (2013) 467–471470phenobarbital and phenytoin only controlled 43% and 45% of
seizures, respectively. Even together, the two AEDs only
controlled seizures in 57–62% of neonates.23 In 542 children,
convulsive status epilepticus terminated after ﬁrst-line treat-
ment in 42%, second-line treatment in 35%, and was refractory in
22%.24 Similarly, in children with convulsive status epilepticus
upon arrival to an emergency department, seizures terminated
after a ﬁrst-line benzodiazepine in 65% (121/187) and after a
second-line AED in 50% (41/82), with 50% (41/82) remaining
refractory and requiring thiopental infusion.25 In a study of
adults with convulsive status epilepticus a median of three AEDs
were administered and only 30% of subjects required two or
fewer AEDs for seizure termination.22
Dosing of AEDs was variable, but averaged 20 mg/kg for each
of the four medications. This dosing is consistent with the recent
Neurocritical Care Society status epilepticus management
guidelines20 but may be on the low end. As described in the
guidelines, second doses of phenytoin or phenobarbital may be
administered at 5–10 mg/kg and dosing may be higher for
valproate (40 mg/kg) and levetiracetam (60 mg/kg). Higher
dosing may have terminated seizures in more patients, although
at these middle doses no difference was found in dosing
between patients in whom seizures did and did not terminate
for any of the AEDs.
This observational study has limitations. First, this was a
single center study which limits generalizability. Different
centers may have different treatment practices regarding the
speed of seizure identiﬁcation, overall management approach,
and speciﬁc AED choices. Thus, the state of equipoise at out
center may not reﬂect an overall state of equipoise across centers.
Surveys regarding AED management and/or multi-center studies
of actual AED use are needed to better evaluate the current
practice across centers. If practice regarding AED choice is not
uniform then this inter-center variability could be harnessed to
perform comparative effectiveness studies evaluating AED
effectiveness.26 Second, AED use was open-label and determined
clinically. Thus, there was likely variability in the manner in
which AEDs were escalated, peak AED doses administered, and
the time interval for progressing to the next AED if seizures
persisted. Treatment delays have been associated with lower
response rates in children with convulsive status epilepti-
cus.25,27,28 However, the knowledge that ES and even ESE
sometimes terminate after administration of available AEDs
indicates that ES-ESE identiﬁcation by cEEG has the potential to
improve outcome using our current pharmacologic armamen-
tarium. This motivates future rigorous comparative effectiveness
studies of the available AEDs and overall management pathways.
Third, seizure burden classiﬁcation and AED refractoriness are
intertwined. Seizures were classiﬁed as ES or ESE at the onset of
AED management. Using this classiﬁcation approach, even 50% of
subjects with ESE had seizure termination with 1–2 AEDs
indicating that ESE is not always a hopeless refractory condition.
These data may have differed had we classiﬁed subjects as having
ESE if they experienced ESE at any point. If ES responded to AED
therapy then it would be unlikely to evolve into ESE. In contrast, if
ES did not respond to AED therapy then it would be more likely to
achieve a sufﬁciently high seizure burden to be classiﬁed as ESE,
thereby making ESE appear even more refractory to AED therapy.
Fourth, this study aimed to describe current AED use and was not
powered to compare the medications. There was a non-
signiﬁcant trend toward seizures terminating more often
following administration of phenobarbital than phenytoin–
fosphenytoin or levetiracetam. However, phenobarbital was
administered more often to younger patients which may bias
the results. Further studies powered to compare AED efﬁcacy are
needed.5. Conclusions
These data indicate that at our center almost all patients with ES
or ESE receive AEDs that AED choice is currently in a state of
equipoise, and that AED administration is often followed by ES and
ESE termination. These data suggest that management is possible
for many patients with ES and ESE using existing AEDs. Further
study is needed to establish whether current practice across
centers is at a similar state of equipoise. This framework will help
ensure that future rigorous comparative effectiveness studies of
AEDs for ES and ESE in critically ill children are designed in a
manner that is ethical and feasible.
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